“…Interest in these materials was renewed in recent years, after it was widely recognized that the incorporation of two or more different molecules in the same crystal could open a variety of opportunities for product innovation [ 2 ] and patenting [ 3 ] in industrial sectors such as dyes [ 4 ], agrochemicals [ 5 ], optics [ 6 , 7 ], energetic materials [ 8 , 9 , 10 ], and pharmaceuticals [ 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ]. Thus, for example, energetic materials made of bi-component crystals with better stability than their individual precursors have been reported [ 8 , 9 , 10 ], and medicines based on bi-component crystals (API-CF) consisting of an active pharmaceutical ingredient (API) and a pharmaceutically acceptable co-former (CF) or two APIs (API–API) have been marketed or are in clinical development [ 19 , 20 ]. In the pharmaceutical area, where the main driving force for research on multi-component crystals currently resides, the goal is typically the improvement and modulation of properties that need to be strictly controlled to warrant the optimal and reproducible performance of a drug (e.g., chemical and physical stability, tabletability, hygroscopicity, solubility, dissolution rate, bioavailability) [ 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ], or the achievement of multimodal therapy [ 21 , 22 ].…”